Serum syndecan‐1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease
- 8 March 2004
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 72 (4), 252-258
- https://doi.org/10.1046/j.0902-4441.2003.00205.x
Abstract
Neovascularisation and bone resorption are related to myeloma disease activity.To investigate the possible prognostic importance of serum syndecan-1, basic fibroblast growth factor (bFGF) and osteoprotegerin (OPG) levels, the relationship between them, with parameters of disease activity and the effect of treatment on their levels.Twenty-seven patients were studied from diagnosis and an additional five from remission, for a median follow-up of 40 months. Twenty-three patients received chemotherapy plus bisphosphonates and nine only bisphosphonates. Sera from 11 healthy individuals (HI) were used as controls. Cytokines were determined by commercially available enzyme-linked immunosorbent assays (ELISA) kits.In HI, median syndecan-1 was 40 ng/mL (28-75), bFGF 8 pg/mL (7-30), OPG 35 pg/mL (4-100). Pretreatment median serum syndecan-1 was 177.5 ng/mL (34-3500), bFGF 11.5 pg/mL (8-65) and OPG 100 pg/mL (4-1000). Pretreatment syndecan-1, bFGF and OPG serum levels were increased in patients compared with HI (P = 0.001, 0.03 and 0.01, respectively). Syndecan-1 and bFGF levels were correlated with stage (P = 0.004 and 0.03, respectively). Both syndecan-1 and OPG levels were correlated with beta2M (P = 0.04 and 0.01, respectively). Patients with elevated syndecan-1 and bFGF serum levels had shorter survival than patients with normal levels (P = 0.01 and 0.05, respectively). After chemotherapy syndecan-1 and OPG levels were found to be decreased in responders and syndecan-1 level was reduced in patients receiving bisphosphonates alone.Pretreatment syndecan-1, bFGF and OPG levels were found to be increased at diagnosis. Syndecan-1 and OPG fluctuated according to MM activity. Elevated serum syndecan-1 and bFGF levels predicted short survival.Keywords
This publication has 36 references indexed in Scilit:
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myelomaEuropean Journal of Haematology, 2001
- Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with OsteoporosisJournal of Bone and Mineral Research, 1999
- Homing behaviour of the malignant cell clone in multiple myelomaMedical Oncology, 1998
- Regulated Shedding of Syndecan-1 and -4 Ectodomains by Thrombin and Growth Factor Receptor ActivationOnline Journal of Public Health Informatics, 1997
- Cloning of a novel membrane-linked metalloproteinase from human myeloma cellsBiochemical Journal, 1996
- Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasisCancer and Metastasis Reviews, 1995
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994
- INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSIONThe Lancet, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958